the aid library

LIST OPTIONS

Filter

12083

Comprehensive Evaluation of the Community Health Program in Rwanda (FINAL REPORT)

Centre for Maternal and Newborn Health (CMNH), from the Liverpool School of Tropical Medicine (LSTM) (2016) C2

The objective of the evaluation is to understand whether the CHW program has achieved its intended objectives, thus contributing to the overarching objectives defined in the HSSP III of improving the health status of the population by “Ensuring universal accessibility of quality health services fo... more

Download (576)

View PDF (767)

Care of the HIV-Exposed Infant

Centers for Disease Control and Prevention (CDC) (2018) C1

This clinical job aid addresses the importance of maternal health and antiretroviral therapy adherence, as well as care and testing for the HIV-exposed infant until the infant’s final HIV diagnosis after the end of breastfeeding.

Download (303)

View PDF (684)

Sudan: Multi-Year Humanitarian Strategy 2017-2019

UN Office for the Coordination of Humanitarian Affairs (2017) C1

Download (76)

View PDF (91)

Epidemiology and Challenges of Managing COPD in sub-Saharan Africa

Magitta, N.F.; Sciences, A. Acta Scientific Medical Sciences (2018) CC2

There is paucity of data on the burden and specific drivers operative in the pathogenesis of chronic obstructive pulmonary disease (COPD) in the African setting and populations. Lack of awareness and inadequate knowledge on the aetio-pathogenesis of the disease together with inadequate capacity for ... more

Download (434)

View PDF (566)

Contextual Factors Influencing Modern Contraceptive Use in Nigeria

Ejembi, Clara Ladi, Tukur Dahiru, and Alhaji A. Aliyu ICF International (2015) C2

DHS Working Papers No. 120

Download (118)

View PDF (342)

The reality of managing asthma in sub-Saharan Africa – Priorities and strategies for improving care

Mortimer, K.; Masekela, R.; Ozoh, O.; et al. (2022) CC2

Asthma is the most common non-communicable disease in children and remains one of the most common throughout the life course. The great majority of the burden of this disease is seen in low-income and middle-income countries (LMICs), which have disproportionately high asthma-related mortality relati... more

Download (280)

View PDF (260)

Monitoring and surveillance of antimicrobial resistance in bacteria from healthy food animals intended for consumption

Food and Agriculture Organization of the United Nations FAO (2019) C2

The animal health subsector within the agriculture sector is the gatekeeper of antimicrobial resistance (AMR) in livestock, aquaculture, animal products, and the immediate animal environment. In support of member countries taking responsibility for and moving forward with putting AMR monitoring and ... more

Download (191)

View PDF (238)

Consolidated strategic information guidelines for HIV in the health sector. Executive Sumary

World Health Organization (2020) C_WHO

Driving Impact through Programme Monitoring and Management These guidelines – an update to the World Health Organization’s 2015 publication Consolidated strategic information guidelines – present a set of essential aggregate indicators and guidance on choosing, collecting and systematically ... more

Download (160)

View PDF (164)

Global Epidemiological Surveillance Standards for Influenza

World Health Organization WHO (2013) C_WHO

Download (281)

View PDF (612)

Haiti: Hurricane Matthew - Situation Report No. 22 (16 November 2016)

UN Office for the Coordination of Humanitarian Affairs (2016) C1

Main Points The delivery of humanitarian assistance is expected to slow down significantly over the next seven to ten days in anticipation of the electoral process and limited availability of transport and security assets. The percentage of extremely food-insecure people who have recei... more

Download (383)

View PDF (534)

Universal Access to HIV/AIDS, Tuberculosis and Malaria Services by A United Africa by 2010

African Union; (2006) C2

Special summit of African Union on HIV and Aids, Tuberculosis and Malaria (atm) Abuja, Nigeria 2–4 may, 2006Sp/Assembly/ATM/2 (I), Rev.3 Abuja call for accelerated action towards universal access to HIV and Aids, Tuberculosis and Malaria services in Africa

Download (584)

View PDF (990)

Yellow fever situation report (28 October 2016)

World Health Organization WHO (2016) C_WHO

Download (182)

View PDF (202)

Nurses as substitutes for doctors in primary care - Review

Laurant M, van der Biezen M, Wijers N et al. Cochrane Library (2018) CC

Current and expected problems such as ageing, increased prevalence of chronic conditions and multi-morbidity, increased emphasison healthy lifestyle and prevention, and substitution for care from hospitals by care provided in the community encourage countries worldwide to develop new models of prima... more

Download (53)

View PDF (59)

Evaluation of serum-based real-time PCR to detect Schistosoma mansoni infection before and after treatment

Fuss, A.; H. D. Mazigo and A. Mueller (2020) CC

Infectious Diseases of Poverty (2020) 9:74 To detect acute schistosomiasis, low-intensity infections, or to verify the success of treatment with praziquantel, highly sensitive test methods are required. The aim of this study was therefore to demonstrate the performance of Schistosoma mansoni spec... more

Download (1292)

View PDF (1075)

The Haiti Health Sector Directory: U.S.-Based Implementers Working in Haiti

USAID, Synergie Project (2003) C1

Download (434)

View PDF (615)

Factors Associated with Changes in Uptake of HIV Testing among Young Women (age 15–24) in Tanzania from 2003 to 2012

Phimemon, Rune N., Michael J. Mahande, and Habib O. Ramadhani ICF International (2015) C2

DHS Working Papers No. 119

Download (764)

View PDF (1571)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (318)

View PDF (454)

Planning, Monitoring and Evaluation. Webinar 14. Companion Technical Booklet

Mont, D. UNICEF (2014)

Download (346)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (476)

View PDF (649)

Toolkit on disability for AFRICA: INFORMATION AND COMMUNICATION TECHNOLOGY (ICT) AND DISABILITY

United Nations Division for Social Policy Development (DSPD) & United Nations Department of Economic and Social Affairs (DESA) (2016) C1

Module 12